• Vaccines.

    British authority: no evidence against AstraZeneca

  • Vaccini, the Public Prosecutor of Catania: "No danger emerges from AstraZeneca"

  • WHO: more deaths in Europe than a year ago

  • Astrazeneca.

    Palù (Aifa): beware of women who take birth control pills

  • Hope: the AstraZeneca case does not undermine confidence in vaccines, answers from Ema already tomorrow

  • Doubts and fear spread across the American continent over the AstraZeneca vaccine

  • Von der Leyen: "On export vaccines we want reciprocity. I trust AstraZeneca, Ema will clarify"

Share

March 18, 2021 "We have come to a conclusion: the AstraZeneca vaccine is effective against coronavirus and the benefits far outweigh the risks, no links have emerged between the vaccine and thromboembolic events. We will carry out specific studies on the side effects, and we remain confident about the vaccines which are fundamental to the challenge we are facing ".

This was stated by Emer Cooke, executive director of the European Medicines Agency (Ema), during a press conference on the review of the Astrazeneca vaccines against Covid-19.



"The conclusion of the EMA review is that it is a safe and effective vaccine."

Emer Cooke said after reviewing AstraZeneca's vaccine-related thrombosis cases.

"We will continue to analyze situations, it is a priority"



Thrombosis cases after administration of the AstraZeneca vaccine are "lower" than those occurring in the unvaccinated population.

This was stated by Sabien Straus, president of the Prac (pharmacovigilance commission) at the press conference of the EMA.



Ema: "Now every country can make an informed decision"

"We know that many member states were waiting for safety indications, what the EMA has done is important to continue with vaccinations. Every country can now make an informed decision".

This was stated by Emer Cooke, executive director of the European Medicines Agency (Ema) during the press conference following the conclusion of the checks on the AstraZeneca vaccine.



The direct




health authority Gb: "No evidence of vaccines cause thrombosis"

"There is no evidence that vaccines against covid produced by AstraZeneca and Pfizer / BioNTech cause thrombosis".

This is what June Raine, executive director of MHRA, the highest British health authority, said in a statement.

"Our thorough and thorough examination - he explained - together with the critical evaluation of leading independent scientists, shows that there is no evidence that venous thrombosis is produced to a greater extent than might be expected in the absence of a vaccine, either. for one vaccine as for the other ".



The British authority then adds that a further detailed analysis of five reported cases in the United Kingdom of a "very rare and specific type of blood thrombus" in the brain is underway, but states that no "causal link" has been established with the vaccine.



Pm Catania: "No danger emerges from AstraZeneca"

To the Public Prosecutor of Catania "there are no elements that allow us to hypothesize that the events on which he is investigating are symptomatic of a danger in the use of the AstraZeneca vaccine, and not even some of its lots, from part of the generality of the subjects towards whom such use is permitted ".

The prosecutor Carmelo Zuccaro states in a note, underlining that "the firmness of this conviction is demonstrated by the fact that the writer and the vast majority of magistrates and staff of this office went to receive the administration of the" AstraZenaca vaccine when the investigation was already open.



WHO, vaccine benefits much greater AstraZeneca res of

those

European countries should continue to administer the vaccine against AstraZeneca Covid-19, as the benefits are much greater than the risks.

This is the appeal that came from Hans Kluge, director of the World Health Organization (WHO) in Europe, after several nations suspended inoculation following some cases of clots that are suspected to be related to serum and in day of the decision of the EMA.

"At the moment, we don't know if any or all of these conditions were caused by the vaccine or by other coincidental factors," said Kluge, "right now, however, the benefits of AstraZeneca's vaccine far outweigh its risks. and its use should continue to save lives. " 



Von der Leyen, respect Ema's work

Even the president of the EU, Ursula Von der Leyen, rejected the doubts about the safety of the drug produced by AstraZeneca, stressing that her evaluation, before the launch of the vaccination campaign, "was very rigorous, I trust the EMA and tomorrow (today for the reader, ed) it will clarify the situation ".

The most likely scenario is that the European regulator reaffirms the total reliability of the vaccine, implicitly recommending to the sixteen governments that have decided to suspend to resume administration.

However, it is also possible that some recommendations will be added in the so-called "leaflet".

Even the Italian health authorities have expressed their most convinced confidence in the positive outcome of the affair.



Draghi: vaccination campaign goes on regardless of Ema's decision

Today, Prime Minister Mario Draghi, who spoke in Bergamo to celebrate the first day of memory of the victims of Covid, specified that whatever Ema's decision, the vaccination campaign will continue.



"The government - and you know it well - is committed to getting as many vaccinations as possible in the shortest possible time. This is our priority."

Thus Prime Minister Mario Draghi, speaking in Bergamo, at the Martin Lutero alla Trucca park, at the inauguration of the Bosco della Memoria in memory of the over one hundred thousand Italian victims of the pandemic.

"The suspension of the AstraZeneca vaccine, implemented on Monday with many other European countries, was a temporary and precautionary decision. Today, the European Medicines Agency will give its final opinion on the matter. Whatever its decision - therefore ensures the Prime Minister - the vaccination campaign will continue with the same intensity, with the same objectives. The increase in the supply of some vaccines will help compensate for delays by other pharmaceutical companies. We have already made decisive decisions towards companies that do not they keep the pacts ".